Currently, the predictive capabilities evaluation of IL-6 in cancer mostly focuses on treatment outcomes or survival status [44,45,46,47,48,49,50], making it one of the most discussed prognostic markers for NSCLC patients. The gene discussed is IL6; the disease is non-small cell lung carcinoma.